VtCD-cTP-ALKF-2
VtCD-cTP-ALKF-2 is a DAPK1 PROTAC degrader. VtCD-cTP-ALKF-2 can bind to dephosphorylated DAPK1, recruit VHL E3 ligase, and induce ubiquitin-proteasome-mediated degradation. VtCD-cTP-ALKF-2 can be used for research on Alzheimer's disease.
(Pink: DAPK1 ligand (HY-P12376); Blue: VHL ligand (HY-125845); Black: linker (HY-22408)).
For research use only. We do not sell to patients.
- Formula: C210H314F12N60O50S3
- Molecular Weight:4803.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All PROTACs Isoforms
More
Biological Activity
Description
In Vitro
VtCD-cTP-ALKF-2 (10 μM; 12-48 h washout monitoring), generated from its caged precursor, induces ROS- and proteasome-dependent DAPK1 degradation with 62% reduction of total DAPK1 and downstream reduction of p-APP and p-Tau in Aβ42 oligomer-induced SH-SY5Y cells[1].
VtCD-cTP-ALKF-2 (100 μM H2O2; 24 h) is generated from its caged precursor with near-complete conversion and remains stable at pH 7.4 without H2O2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 4803.29
-
Formula C210H314F12N60O50S3
-
SMILES
OC1=CC=C(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCCN)NC([C@@H](CC2)CC[C@@H]2C(N[C@H](C(N3[C@@H](C[C@H](C3)O)C(NCC4=CC=C(C5=C(C)N=CS5)C=C4)=O)=O)C(C)(C)C)=O)=O)=O)CCCCN)=O)CC(N)=O)=O)CCCNC(N)=N)=O)CC(N)=O)=O)CCCCN)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CC6=CNC=N6)=O)CO)=O)C(NCCCCCC(N[C@H]7CSC(C8=O)CC(N8CCC(OCC(F)(C(F)(C(F)(C(F)(C(F)(C(F)(COC(CCN9C(CC(C9=O)SC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC7=O)CC%10=CNC=N%10)=O)CC(C)C)=O)CC(N)=O)=O)[C@H](CC)C)=O)CC(C)C)=O)CO)=O)[C@@H](C)O)=O)CC(C)C)=O)CC%11=CNC%12=CC=CC=C%12%11)=O)CCCCN)=O)CC%13=CC=C(O)C=C%13)=O)CCCNC(N)=N)=O)C(N)=O)=O)=O)F)F)F)F)F)F)=O)=O)=O)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VtCD-cTP-ALKF-2 Related Classifications
HY-188197 Related Classifications
Powered by Bioz